Q32 Bio to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Rhea-AI Summary

Q32 Bio (Nasdaq: QTTB) said management will appear in a fireside chat at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on Wednesday, February 25, 2026 at 2:00 p.m. ET.

A live webcast will be available on Q32 Bio's Events and Presentations page, with archived replays accessible for 90 days after the event.

News Market Reaction – QTTB

-5.37%

3 alerts

-5.37% Session close to close

+12.2% Peak Tracked

$52.54M Market Cap

0.3x Rel. Volume

In the Feb 18 session, QTTB declined 5.37%, reflecting a notable negative market reaction. Argus tracked a peak move of +12.2% during that session. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved -5.4% in the session following this news. A negative reaction despite positive or ne...

Analysis

The stock moved -5.4% in the session following this news. A negative reaction despite positive or neutral corporate communication would fit a pattern seen after some recent clinical and earnings updates, where shares fell even on constructive news. Given the stock’s advance from its 52-week low and position above the 200-day average, profit-taking or sensitivity to financing and development risk could have amplified downside. Earlier events, including SIGNAL-AA milestones, showed that pipeline progress alone did not always support the share price.

Key Figures

Conference time: 2:00 p.m. E.T. Conference date: February 25, 2026 Conference edition: 36th +1 more

4 metrics

Conference time 2:00 p.m. E.T. Scheduled fireside chat on February 25, 2026

Conference date February 25, 2026 Oppenheimer 36th Annual Healthcare Life Sciences Conference

Conference edition 36th Oppenheimer Annual Healthcare Life Sciences Conference

Replay window 90 days Archived webcast replay availability after the event

Historical Context

4 past events · Latest: Dec 01 (Positive)

Pattern 4 events

Date	Event	Sentiment	24h Move	Catalyst
Dec 01	Asset sale / funding	Positive	+74.4%	Sold ADX-097 with upfront, milestones and royalties extending cash runway.
Nov 13	Earnings and update	Positive	-9.1%	Reported Q3 2025 results and progress on SIGNAL-AA Part B enrollment.
Oct 21	Clinical trial update	Positive	-10.8%	Completed Part B enrollment in SIGNAL-AA Phase 2a for bempikibart in AA.
Aug 28	Conference participation	Neutral	+2.9%	Announced Wells Fargo Healthcare Conference fireside chat and webcast access.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Positive clinical and earnings updates have previously seen mixed or negative price reactions, while asset monetization and conference participation have drawn more favorable responses.

Recent Company History

Over the past six months, Q32 Bio has advanced its alopecia areata program and reshaped its portfolio. On Oct 21, 2025, it completed enrollment in Part B of the SIGNAL-AA Phase 2a trial, yet shares fell despite emerging clinical activity. The Nov 13, 2025 earnings update highlighted completed enrollment and a cash position of $49.0M, but the stock again declined. By Dec 1, 2025, the company monetized ADX-097 for up to $592M in milestones, which drove a strong positive reaction. A 2025 Wells Fargo conference appearance saw a modest gain, similar in nature to today’s Oppenheimer conference news.

Key Terms

alopecia areata (aa)

1 terms

alopecia areata (aa) medical

"developing innovative therapies for alopecia areata (AA) and other autoimmune"

Alopecia areata is an autoimmune condition that causes hair to fall out in round patches when the immune system mistakenly attacks hair follicles; it can range from small bald spots to complete loss of scalp or body hair. Investors care because the condition creates a measurable patient population and ongoing demand for treatments, so trial results, regulatory decisions, or new therapies can meaningfully affect company sales and valuation—like a small market shift triggering larger ripples in a pond.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WALTHAM, Mass., Feb. 18, 2026 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, today announced that management will participate in a fireside chat at 2:00 p.m. E.T. on Wednesday, February 25, 2026 at the Oppenheimer 36^th Annual Healthcare Life Sciences Conference.

A webcast of the presentation will be available on the Events and Presentations page of Q32 Bio's website at www.q32bio.com. Archived replays will be available for 90 days following the event.

About Q32 Bio

Q32 Bio is a clinical stage biotechnology company whose science targets potent regulators of the adaptive immune system to re-balance immunity and is focused on developing innovative therapies for alopecia areata and other autoimmune and inflammatory diseases. About 700,000 people in the United States live with alopecia areata¹, a disease which has a life-altering impact on patients and limited current treatment options. Q32 Bio is advancing bempikibart (ADX-914), a fully human anti-IL-7Rα antibody that re-regulates adaptive immune function, for the treatment of alopecia areata in an ongoing Phase 2 program. The IL-7 and TSLP pathways have been genetically and biologically implicated in driving several T cell-mediated pathological processes in numerous autoimmune diseases.

For more information, visit www.Q32Bio.com.

¹National Alopecia Areata Foundation

Availability of Other Information About Q32 Bio

Investors and others should note that Q32 Bio communicates with its investors and the public using its website www.Q32Bio.com, including, but not limited to, Q32 Bio's disclosures, investor presentations and FAQs, Securities and Exchange Commission (the "SEC") filings, press releases, public conference call transcripts and webcast transcripts, as well as on X (formerly Twitter) and LinkedIn. The information that Q32 Bio posts on its website or on X or LinkedIn could be deemed to be material information. As a result, Q32 Bio encourages investors, the media and others interested to review the information that it posts there on a regular basis. The contents of Q32 Bio's website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.

Contacts:

Investors: Brendan Burns
Argot Partners
212.600.1902
Q32Bio@argotpartners.com

Media: David Rosen
Argot Partners
646.461.6387
david.rosen@argotpartners.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/q32-bio-to-participate-in-the-oppenheimer-36th-annual-healthcare-life-sciences-conference-302689781.html

SOURCE Q32 Bio

FAQ

When will Q32 Bio (QTTB) present at the Oppenheimer Healthcare Life Sciences Conference?

Q32 Bio will present on Wednesday, February 25, 2026 at 2:00 p.m. ET. According to the company, the session is a fireside chat during the Oppenheimer 36th Annual Healthcare Life Sciences Conference and is aimed at investors and analysts.

How can investors watch Q32 Bio (QTTB) at the February 25, 2026 conference?

Investors can watch via live webcast on Q32 Bio's Events and Presentations webpage. According to the company, the webcast link will be posted on www.q32bio.com and a replay will be available for 90 days.

Will Q32 Bio (QTTB) make the presentation available after the conference?

Yes, an archived replay will be available for 90 days after the event. According to the company, the replay will be posted on the Events and Presentations page of its website for on-demand viewing.

What topics will Q32 Bio (QTTB) likely cover in the February 25, 2026 fireside chat?

The company will discuss its clinical-stage programs in alopecia areata and related autoimmune research. According to the company, management will cover recent progress, development plans, and corporate updates relevant to investors.

Where is the webcast of Q32 Bio's (QTTB) Oppenheimer presentation hosted?

The webcast is hosted on Q32 Bio's Events and Presentations page at www.q32bio.com. According to the company, the page will provide the live stream link and subsequent archived replay for 90 days.